Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized, Double-blind, Placebo-controlled, Study of Zatolmilast (BPN14770) in Subjects With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome)

Next Previous
Trial Profile

A Phase 2 Randomized, Double-blind, Placebo-controlled, Study of Zatolmilast (BPN14770) in Subjects With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zatolmilast (Primary)
  • Indications Neurodevelopmental disorders
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Shionogi

Most Recent Events

  • 09 Jun 2026 A new primary efficacy endpoint, Change From Baseline at Week 24 in Numerical Rating Scale Within the Domain of Language/Communication, has been added. The assessment period for safety endpoints (TEAEs, seizures, suicidality, and DESS) has been extended from approximately 48-50 weeks to 96-98 weeks.
  • 09 Jun 2026 Planned End Date changed from 31 Jan 2030 to 31 Dec 2027.
  • 09 Jun 2026 Planned primary completion date changed from 31 Jan 2030 to 31 Dec 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top